UTHR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
UTHR is not a good buy right now for an impatient buyer. Price is sitting near the pivot (~468) with weakening momentum (MACD below zero) and probabilistic near-term drift slightly negative; there is no Intellectia buy signal to override that.
Intellectia Proprietary Trading Signals
Net: despite constructive fundamentals and a positive R&D headline, the current setup looks more like a “wait/hold” than an immediate entry.
Trend/momentum is mixed to slightly bearish near-term. MACD histogram is negative (-0.947) but contracting (downtrend pressure easing, not yet reversed). RSI(6)=41.92 is neutral-to-soft (not oversold). Moving averages are converging, consistent with consolidation rather than a strong uptrend. Key levels: pivot 468.293 (price ~469.49 is just above it), resistance at 477.377 then 482.989; support at 459.209 then 453.597. With price near the pivot and below nearby resistances, risk/reward is not compelling for an immediate buy unless it reclaims and holds above ~477–483.
Earnings catalyst upcoming: QDEC 2025 earnings on 2026-02-24 (pre-market). Continued YoY growth in revenue, net income, and EPS supports the bull case.
Near-term technical momentum is not yet bullish (MACD below zero; consolidation under resistance). Pattern-based forward look provided suggests modest downside bias (70% chance of -1.32% next day; slightly negative over next week/month). Elevated IV implies the market expects notable moves (event risk premium). No notable supportive flow from insiders/hedge funds in the provided data (both neutral). No recent congress trading data available (no political-flow tailwind identified).
Latest reported quarter: 2025/Q3. Revenue grew to $799.5M (+6.76% YoY). Net income rose to $338.7M (+9.58% YoY) and EPS increased to 7.16 (+12.05% YoY), indicating improving profitability and solid operational leverage. Gross margin dipped to 87.38% (-1.71% YoY), a mild negative but still very high margin overall. Overall: steady growth trend with a small margin headwind.
Recent analyst activity is supportive: UBS reiterated Buy and raised its price target twice (to $600 from $580 on 2025-11-06; to $645 from $600 on 2026-01-06). Wall Street pro view (from the provided data) skews bullish on sector positioning and potential M&A tailwinds; the con is that broader biotech performance may depend on sustained M&A outpacing secondary/IPO supply and UTHR still needs continued execution and catalysts to justify upside versus current consolidation.
